A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

D C McMillan, S J Wigmore, K C Fearon, P O'Gorman, C E Wright, C S McArdle

Research output: Contribution to journalArticlepeer-review

Abstract

The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P
Original languageEnglish
Pages (from-to)495-500
Number of pages6
JournalBritish Journal of Cancer
Volume79
Issue number3-4
DOIs
Publication statusPublished - 1999

Fingerprint Dive into the research topics of 'A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss'. Together they form a unique fingerprint.

Cite this